Oneness Biotech Co., Ltd. (LUX:ONES)

Market Cap	929.97M
Revenue (ttm)	3.47M
Net Income (ttm)	-34.33M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	9.75
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
RSI	37.22
Earnings Date	Mar 7, 2025

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan. It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the tre...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 43
• Stock Exchange: Luxembourg Stock Exchange
• Ticker Symbol: ONES

Financial Performance

In 2024, Oneness Biotech's revenue was 117.93 million, an increase of 35.89% compared to the previous year's 86.78 million. Losses were -1.17 billion, -11.25% less than in 2023.

Financial numbers in TWD